Scientists from the University of Eastern Finland have identified alterations occurring in the human brain that signal the early stages of this common neurogenerative disease.
Prescribing low-dose aspirin for preventing secondary cardiovascular disease is well established, but its safety and efficacy in primary prevention remains open to debate.